Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia

NCT07674823 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT07674823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07674823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
April 1, 2031
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia